| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-131 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持股的基本情况 本次减持计划实施前，上海皓元医药股份有限公司（以下简称"公司"）股 东苏民投君信（上海）产业升级与科技创新股权投资合伙企业（有限合伙）（以 下简称"苏信基金"）持有公司 546,405 股股份，占减持计划实施前公司总股本 的 0.26%。上述股份为公司首次公开发行前及上市后权益分派资本公积转增股本 取得的股份，并已上市流通。 减持计划的实施结果情况 公司于 2025 年 12 月 22 日在上海证券交易所网站（www.sse.com.cn）披露 了《上海皓元医药股份有限公司股东减持股份计划公告》（公告编号：2025-130）。 苏信基金拟通过集中竞价的方式减持不超过 546,405 股公司股份，拟减持比例不 超过减持计划实 ...

从资金流向上来看，当日医疗服务板块主力资金净流出8.24亿元，游资资金净流入4129.99万元，散户资 金净流入7.83亿元。医疗服务板块个股资金流向见下表： 证券之星消息，12月26日医疗服务板块较上一交易日下跌0.21%，皓元医药领跌。当日上证指数报收于 3963.68，上涨0.1%。深证成指报收于13603.89，上涨0.54%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600721 | 自花医药 | 12.24 | 5.88% | 48.95万 | | 5.94亿 | | 301096 | 百诚医药 | 55.93 | 3.79% | 5.12万 | | 2.84亿 | | 000504 | *ST生物 | 9.20 | 3.25% | 2.70万 | | 2461.38万 | | 301201 | 诚达药业 | 41.95 | 0.84% | 6.37万 | | 2.72亿 | | 603259 | 药明康德 | 92.70 | 0. ...

Core Viewpoint - The company, Haoyuan Pharmaceutical, is actively expanding its global presence and enhancing its operational efficiency, as evidenced by its recent performance and strategic initiatives [1] Group 1: Business Operations - The company has established 8 business centers, 6 research centers, and 4 production bases across various regions including China, the USA, Europe, India, Hong Kong, Japan, South Korea, and Southeast Asia [1] - The company utilizes a cross-regional collaboration mechanism between domestic professionals and international business personnel to quickly respond to the needs of over 10,000 global clients [1] Group 2: Partnerships and Collaborations - The company has formed partnerships with multiple multinational pharmaceutical giants, renowned global universities, research institutions, and CRO companies [1] - Stable collaborations have been established with numerous well-known overseas distributors specializing in drug research reagents [1] Group 3: Revenue Performance - In the first half of 2025, the company's overseas revenue reached 560 million yuan, representing a year-on-year growth of 39.8% [1] - Overseas revenue accounted for 43.0% of the main business income, an increase of nearly 5 percentage points compared to the previous year [1] - The company has achieved same-day order and next-day delivery in most regions of the USA and China, providing a convenient purchasing experience that outperforms imported brands [1]

（文章来源：证券日报） 证券日报网讯 12月21日晚间，皓元医药发布公告称，股东苏信基金拟于2025年12月26日至2026年3月25 日通过集中竞价减持不超过546，405股，占公司总股本0.26%，减持原因为基金到期、股东自身财务需 求等安排。 ...

公告显示，苏信基金持有公司54.64万股股份，占减持计划实施前公司总股本的0.26%。这也意味着，此 次减持系清仓式减持。 北京商报讯（记者 丁宁）12月21日晚间，皓元医药（688131）发布公告称，因基金到期、股东自身财 务需求等安排，公司股东苏民投君信（上海）产业升级与科技创新股权投资合伙企业（有限合伙）（以 下简称"苏信基金"）拟通过集中竞价的方式减持不超过54.64万股公司股份，拟减持比例不超过公司当 前总股本的0.26%。 ...

Investment Rating - The industry investment rating is "Overweight" [1] Core Views - The biopharmaceutical investment and financing environment has shown significant recovery since the second half of 2025, with a total financing amount of USD 30.32 billion from July to November 2025, representing a year-on-year increase of 30.90% [4] - The number of new drug IND applications stabilized in 2025, with approximately 1,897 applications from January to November, reflecting a year-on-year growth of about 7.91% [4] - The demand for CRO services has shown a clear turning point, and the report continues to recommend opportunities in the innovative drug industry chain (CXO + research services) for 2026 [4] Summary by Sections Industry Performance - The biopharmaceutical sector experienced a decline of 0.14% in the third week of December 2025, outperforming the CSI 300 index by 0.14 percentage points, ranking 22nd among 31 sub-industries [7][14] - The offline pharmacy sector saw the highest increase, rising by 5.59%, while the chemical preparation sector had the largest decline at 2.1% [18][22] Investment Opportunities - The report highlights the strong performance of leading CXO and research service companies, with many exceeding earnings expectations. Companies like WuXi AppTec and Tigermed have raised their earnings guidance for 2025 [5] - The report recommends a valuation switch opportunity for leading CXO and research service companies, given the continuous improvement in demand [5] Clinical Research Organizations (CRO) - There has been a notable improvement in orders for preclinical and clinical CROs, with expectations for significant improvements in financial statements for 2026 [6] - The report anticipates that the market demand will continue to focus on leading companies as the capacity of clinical CROs is expected to be streamlined [6] Monthly and Weekly Recommendations - The report recommends a monthly investment portfolio including companies such as Sanofi, Innovent Biologics, and others, focusing on innovative drug opportunities and valuation switch [8]

每经AI快讯，12月21日，皓元医药(688131.SH)公告称，股东苏信基金因基金到期、股东自身财务需求 等安排，拟通过集中竞价方式减持不超过54.64万股公司股份，占公司当前总股本的0.26%。减持期间为 2025年12月26日至2026年3月25日。拟减持股份来源为公司首次公开发行前及上市后权益分派资本公积 转增股本取得的股份。 ...

人民财讯12月21日电，皓元医药(688131)12月21日公告，持股0.26%的股东苏民投君信(上海)产业升级与 科技创新股权投资合伙企业(有限合伙)(简称"苏信基金")拟通过集中竞价方式，减持公司股份不超过 54.64万股，拟减持比例不超过公司当前总股本的0.26%。 ...

| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-130 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 因基金到期、股东自身财务需求等安排，苏信基金拟通过集中竞价的方式减 持不超过 546,405 股公司股份，拟减持比例不超过公司当前总股本的 0.26%。本 次减持计划自本公告披露之日起 3 个交易日后的 3 个月内进行。 近日，公司收到股东苏信基金出具的《关于股份减持计划的告知函》，现将 具体情况公告如下： | 股东名称 | 苏民投君信（上海）产业升级与科技创新股权投资合伙 | | | --- | --- | --- | | | 企业（有限合伙） | | | 股东身份 | 控股股东、实控人及一致行动人 √否 | □是 | | | 直接持股 √否 5%以上股东 | □是 | 一、减持主体的基本情况 1 | | 董事、监 ...

智通财经APP讯，皓元医药(688131.SH)发布公告，因基金到期、股东自身财务需求等安排，苏信基金 拟通过集中竞价的方式减持不超过54.64万股公司股份，拟减持比例不超过公司当前总股本的0.26%。本 次减持计划自公告披露之日起3个交易日后的3个月内进行。 ...